Benoît Ferment

4PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

|Feb 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|Sep 18, 2025
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

B Ferment, J Lambert, D Caillot

Pageof 1

Frequent Collaborators

3 joint publications

Xavier Leleu

3 joint publications

Aurore Perrot

3 joint publications

Pierre Bories

3 joint publications

Jill Corre